Biotech · Private company
ProQR Therapeutics
Track this companyFree. Adds ProQR Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- sepofarsenPhase 3 · Leber Congenital Amaurosis 10ClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 3 · Leber Congenital Amaurosis 10ClinicalTrials.gov · fetched Nov 12, 2026
- QR-010Phase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- QR-1123Phase 2 · Autosomal Dominant Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- QR-421aPhase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- Sham procedurePhase 2 · Autosomal Dominant Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- Sham-procedure (dose cohort 1&2 only)Phase 2 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GenePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 7, 2019ClinicalTrials.gov NCT04123626 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 4, 2019ClinicalTrials.gov NCT03913143 · fetched Nov 12, 2026
- Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GenePHASE1_PHASE2 · COMPLETED · started Mar 6, 2019ClinicalTrials.gov NCT03780257 · fetched Nov 12, 2026
- Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR MutationPHASE1 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02564354 · fetched Nov 12, 2026
- Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis PatientsPHASE1_PHASE2 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02532764 · fetched Nov 12, 2026